2019, Number 2
Next >>
Rev Hematol Mex 2019; 20 (2)
Immunology and lymphoma. Two concepts that will always be united
Villela L, Hernández-Hernández JA, López-Sánchez R, García-Zamudio V
Language: Spanish
References: 5
Page: 65-68
PDF size: 205.11 Kb.
Text Extraction
No abstract.
REFERENCES
Delves PJ, Roitt IM. The immune system. Second of two parts. N Engl J Med 2000;343:108-117.
Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 2005;5:201-214.
Kahl BS, Hong F, Williams ME, et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. J Clin Oncol 2014;32(28):3096-102.
Erbe AK, Wang W, Carmichael L, et al. Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab. J Immunother Cancer 2019;7(1):70. doi: 10.1186/s40425-019-0538-8.
Du J, Lopez-Verges S, Pitcher BN, et al. CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res 2014;2(9):878-89.
Full text